Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi Raises INNOVENT BIO's TP to HKD90; New Phase Begins
Recommend 7 Positive 11 Negative 8 |
||||
|
||||
|
INNOVENT BIO (01801.HK)'s IBI363 (PD-1/IL-2alpha-bias bispecific antibody fusion protein product) has been highlighted by opinion leaders for its promising data and potential to become a key product in next-generation immuno-oncology (IO) treatment, Citi published a research report noting. In Citi's opinion, INNOVENT BIO may offer a broader range, more efficient, and less toxic innovative cancer treatments. The company also maintains its target of achieving RMB20 billion in product revenue by 2027 and advancing five pipeline assets into global multi-regional clinical trial (MRCT) Phase 3 by 2030. As INNOVENT BIO has entered a new phase on the back of strong commercial performance and global innovation, Citi raised its target price from HKD60 to HKD90, with a Buy rating remaining in place. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
